Nordic Nanovector: Abstracts of LYMRIT 37-01 Study With Betalutin® in NHL Patients and Other Studies Accepted for Poster Presentations at ASH

OSLO, Norway, Oct. 2, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting data from the Phase 1/2a LYMRIT 37-01 study investigating Betalutin® (177Lu-lilotomab satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin's lymphoma (iNHL)...

from PR Newswire: //https://ift.tt/2y9JvZ9